Congress returns for lame-duck session
Only 3 of 12 spending bills passed; Dec 11 funding deadline fight begins. Outgoing GOP majority may rush full-year funding.
Market is already on edge (VIX above 25 after the Nov 5 AI selloff). The two biggest swing events are Tuesday's CPI and Nvidia's report on Nov 17; the Fed decision (Dec 9) and shutdown deadline (Dec 11) sit just beyond this window.
Dated events and what's in play all week.
Only 3 of 12 spending bills passed; Dec 11 funding deadline fight begins. Outgoing GOP majority may rush full-year funding.
Progress has cut oil 4–7% in a day; lower oil eases inflation but hits energy stocks. A breakdown flips this red.
Nov 5 selloff (S&P −4%, chips −12%) came from fears ~45% of planned US capacity could be restricted.
September CPI was the hottest in 5 months on energy. Another hot print raises odds of a December Fed hike.
No tariff snap-back this week; the cliff moves to January.
Thinner liquidity can exaggerate moves around CPI.
Wholesale inflation confirms or softens the CPI read.
Scheduled events for the following week.
Reported valuation cut to ~$1–1.3T from ~$2T; a gauge of appetite for AI.
Gauge of consumer strength into the holidays.
Housing and consumer-spending read.
The single biggest event for AI stocks — binary after the 9% drop on Nov 5. A beat could spark a relief rally; a miss could extend the selloff.
Two officials voted to hike in October; minutes may show more support for a December hike.
Retail and cybersecurity reads; tariff commentary.
Could extend trade peace or flare tensions over Taiwan, chips and export controls.
Consumer health and China read.
Large expirations can amplify moves into the close.
Beyond the two-week window, or could hit at any time.
Fed hiked in September and held at 3.75–4%. Strong October jobs (165K vs 65K expected) raised hike odds.
Lame-duck Congress must pass funding; shutdowns can delay economic data.
Open since March; a surprise announcement could be large.
Tighter controls on Huawei/SMIC and Taiwan tension weigh on chips.
Outside USMCA exemptions; escalation risk.
Rate changes hit drug makers.
Plans to force votes on Trump tariffs (good for importers) and to scrutinize AI, banks and crypto.
If not renewed, higher China tariffs could return and Beijing could retaliate.